- 1 -

SEQUENCE LISTING

<110> Bayer AG, BHC

<120> Diagnostics and Therapeutics for Diseases Associated with Kallikrein 9 (KLK9)

<130> Le A 36 871

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 753

<212> DNA

<213> Homo sapiens

<400> 1

```
atgaagctgg gactcctctg tgctctgctc tctctgctgg cagggcatgg ctgggcagac    60
acccgtgcca tcggggccga ggaatgtcgc cccaactccc agccttggca ggccggcctc   120
ttccacctta ctcggctctt ctgtgggggcg accctcatca gtgaccgctg gctgctcaca   180
gctgcccact gccgcaagcc gtatctgtgg gtccgccttg gagagcacca cctctggaaa   240
tgggagggtc cggagcagct gttccgggtt acggacttct tcccccaccc tggcttcaac   300
aaggacctca cgccaatga ccacaatgat gacatcatgc tgatccgcct gcccaggcag   360
gcacgtctga gtcctgctgt gcagcccctc aacctcagcc agacctgtgt ctccccaggc   420
atgcagtgtc tcatctcagg ctggggggcc gtgtccagcc caaggcgct gtttccagtc   480
acactgcagt gtgccaacat cagcatcctg agaaacaaac tctgtcactg ggcatacccct   540
ggacacatct cggacagcat gctctgtgcg ggcctgtggg agggggggccg aggttcctgc   600
cagggtgact ctggggggccc cctggtttgc aatggaacct ggcaggcgt ggtgtctggg   660
ggtgctgagc cctgctccag accccggcgc cccgcagtct acaccagcgt atgccactac   720
cttgactgga tccaagaaat catggagaac tga                                 753
```

<210> 2

<211> 250

<212> PRT

<213> Homo sapiens

<400> 2

```
Met Lys Leu Gly Leu Leu Cys Ala Leu Leu Ser Leu Leu Ala Gly His
1               5                   10                  15
Gly Trp Ala Asp Thr Arg Ala Ile Gly Ala Glu Glu Cys Arg Pro Asn
                20                  25                  30
Ser Gln Pro Trp Gln Ala Gly Leu Phe His Leu Thr Arg Leu Phe Cys
            35                  40                  45
Gly Ala Thr Leu Ile Ser Asp Arg Trp Leu Leu Thr Ala Ala His Cys
        50                  55                  60
Arg Lys Pro Tyr Leu Trp Val Arg Leu Gly Glu His His Leu Trp Lys
65                  70                  75                  80
Trp Glu Gly Pro Glu Gln Leu Phe Arg Val Thr Asp Phe Phe Pro His
                85                  90                  95
```

```
        Pro Gly Phe Asn Lys Asp Leu Ser Ala Asn Asp His Asn Asp Asp Ile
                    100             105             110
        Met Leu Ile Arg Leu Pro Arg Gln Ala Arg Leu Ser Pro Ala Val Gln
                    115             120             125
 5      Pro Leu Asn Leu Ser Gln Thr Cys Val Ser Pro Gly Met Gln Cys Leu
                130             135             140
        Ile Ser Gly Trp Gly Ala Val Ser Ser Pro Lys Ala Leu Phe Pro Val
        145             150             155             160
        Thr Leu Gln Cys Ala Asn Ile Ser Ile Leu Glu Asn Lys Leu Cys His
10                  165             170             175
        Trp Ala Tyr Pro Gly His Ile Ser Asp Ser Met Leu Cys Ala Gly Leu
                    180             185             190
        Trp Glu Gly Gly Arg Gly Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu
                    195             200             205
15      Val Cys Asn Gly Thr Leu Ala Gly Val Val Ser Gly Gly Ala Glu Pro
                210             215             220
        Cys Ser Arg Pro Arg Arg Pro Ala Val Tyr Thr Ser Val Cys His Tyr
        225             230             235             240
        Leu Asp Trp Ile Gln Glu Ile Met Glu Asn
20                      245             250
        <210>  3
        <211>  19
        <212>  DNA
        <213>  artificial sequence
25      <220>
        <223>  forward primer
        <400>  3
        gcgctgtttc cagtcacac                                          19
        <210>  4
30      <211>  21
        <212>  DNA
        <213>  artificial sequence
        <220>
        <223>  reverse primer
35      <400>  4
        gcccagtgac agagtttgtt c                                       21
        <210>  5
        <211>  24
        <212>  DNA
40      <213>  artificial sequence
        <220>
        <223>  probe
        <400>  5
        cagtgtgcca acatcagcat cctg                                    24
```

Fig. 1

SEQ ID NO: 1

ATGAAGCTGGGACTCCTCTGTGCTCTGCTCTCTCTGCTGGCAGGGCAT
GGCTGGGCAGACACCCGTGCCATCGGGGCCGAGGAATGTCGCCCCAAC
TCCCAGCCTTGGCAGGCCGGCCTCTTCCACCTTACTCGGCTCTTCTGT
GGGGCGACCCTCATCAGTGACCGCTGGCTGCTCACAGCTGCCCACTGC
CGCAAGCCGTATCTGTGGGTCCGCCTTGGAGAGCACCACCTCTGGAAA
TGGGAGGGTCCGGAGCAGCTGTTCCGGGTTACGGACTTCTTCCCCCAC
CCTGGCTTCAACAAGGACCTCAGCGCCAATGACCACAATGATGACATC
ATGCTGATCCGCCTGCCCAGGCAGGCACGTCTGAGTCCTGCTGTGCAG
CCCCTCAACCTCAGCCAGACCTGTGTCTCCCCAGGCATGCAGTGTCTC
ATCTCAGGCTGGGGGGCCGTGTCCAGCCCCAAGGCGCTGTTTCCAGTC
ACACTGCAGTGTGCCAACATCAGCATCCTGGAGAACAAACTCTGTCAC
TGGGCATACCCTGGACACATCTCGGACAGCATGCTCTGTGCGGGCCTG
TGGGAGGGGGGCCGAGGTTCCTGCCAGGGTGACTCTGGGGGCCCCCTG
GTTTGCAATGGAACCTTGGCAGGCGTGGTGTCTGGGGGTGCTGAGCCC
TGCTCCAGACCCCGGCGCCCCGCAGTCTACACCAGCGTATGCCACTAC
CTTGACTGGATCCAAGAAATCATGGAGAACTGA

Fig. 2

SEQ ID NO: 2

MKLGLLCALLSLLAGHGWADTRAIGAEECRPNSQPWQAGLFHLTRLFC

GATLISDRWLLTAAHCRKPYLWVRLGEHHLWKWEGPEQLFRVTDFFPH

PGFNKDLSANDHNDDIMLIRLPRQARLSPAVQPLNLSQTCVSPGMQCL

ISGWGAVSSPKALFPVTLQCANISILENKLCHWAYPGHISDSMLCAGL

WEGGRGSCQGDSGGPLVCNGTLAGVVSGGAEPCSRPRRPAVYTSVCHY

LDWIQEIMEN

Fig. 3

SEQ ID NO: 3

5'-gcgctgtttccagtcacac-3'

Fig. 4

SEQ ID NO: 4

5'-gcccagtgacagagtttgttc-3'

Fig. 5

SEQ ID NO: 5

5'-cagtgtgccaacatcagcatcctg-3'